Celgene Corporation announced changes to its Board of Directors. Gilla Kaplan, Ph.D., Celgene's longest-standing Director, is retiring from the Board and will not stand for reelection at the upcoming Annual Meeting of Stockholders to be held on June 13, 2018. Patricia “Pat” Hemingway Hall and Hans Bishop have been elected to Celgene’s Board of Directors. Dr. Kaplan has served as Director since April 1998. She has provided important scientific perspective and leadership from her distinguished career in medical research, including her current role as Director of the Global Health Program for Tuberculosis at the Bill and Melinda Gates Foundation. Ms. Hemingway Hall has more than 30 years of experience with a focus on the US health insurance market. She most recently was CEO of Health Care Service Corporation (HCSC), the nation’s largest mutual health insurance company, which operates as Blue Cross and Blue Shield in Illinois, Montana, New Mexico, Oklahoma and Texas, from 2008 until her retirement in 2015. Mr. Bishop is a 30-year industry veteran and was most recently President and CEO of Juno Therapeutics, a cellular immunotherapy company that he co-founded in 2013 and led until Juno was acquired by Celgene in March 2018.